[Use of bevacizumab in the treatment of complicated proliferative diabetic retinopathy].

Abstract

INTRODUCTION:

Diabetes is the leading cause of neovascular vitreoretinal proliferation. Several recent publications have appeared showing the efficacy and safety of intravitreal bevacizumab (IVT) in proliferative or complicated diabetic retinopathy (PDR), but with no consensus on the injected dose. We report the results of its use as adjuvant intravitreal injection (IVT) prior to posterior vitrectomy in the setting of complicated PDR. The goal of our work is to evaluate the benefits of and try to establish a protocol for proper use of intravitreal bevacizumab prior to vitrectomy for complicated PDR, so as to incorporate it in the management of this disease.

PATIENTS AND METHODS:

A prospective comparative study of series of patients hospitalized for severe complicated PDR requiring vitrectomy was spread over one year, from January 2011 to December 2011. Included patients were divided into two groups: group A: receiving an injection preoperatively at a dose of 1.25mg, and group B, which received an injection of bevacizumab at a dose of 0.75mg (with a time to surgery of either less than 3 days, more than 6, or 3 to 6). We analyzed the epidemiological characteristics, data from the initial eye examination and intraoperative complications and follow-up after vitrectomy.

RESULTS:

Thirty-five patients were included. We noted no significant difference in epidemiological characteristics between group A and B. Sixty percent of patients underwent surgery after a period of three to six days post-IVT. The reduction of neovascularization, decreased risk of bleeding and the facilitation of membrane peeling during surgery were significantly similar between group A and B. No complication related to the molecule and no recurrence, including bleeding, were noted throughout follow-up in both groups.

CONCLUSION:

We opt for a systematic use of anti-VEGF, particularly bevacizumab prior to all vitrectomies for complicated PDR. A 0.75mg dose at an interval of 3 to 6 days seems to be a good compromise between the desired effect and possible complications that may arise.

• Authors: L Benhmidoune, A McHachi, M Boukhrissa, A Chakib, R Rachid, M Elbelhadji, A Amraoui
• Journal: Journal francais d'ophtalmologie (J Fr Ophtalmol) Vol. 36 Issue 9 Pg. 758-63 (Nov 2013) ISSN: 1773-0597 [Electronic] France
• Vernacular Title: Utilisation du bévacizumab dans le traitement de la rétinopathie diabétique proliférative compliquée.
• PMID: 23830522 (Publication Type: English Abstract, Journal Article)
• Copyright: Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal, Humanized
• Bevacizumab

Topics

• Adult
• Aged
• Aged, 80 and over
• Angiogenesis Inhibitors (therapeutic use)
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Bevacizumab
• Combined Modality Therapy
• Diabetic Retinopathy (complications, drug therapy, surgery)
• Female
• Humans
• Intraoperative Complications (epidemiology)
• Male
• Middle Aged
• Postoperative Complications (epidemiology)
• Vitrectomy
• Vitreoretinopathy, Proliferative (complications, drug therapy, surgery)
• Young Adult